How to improve the implementation of guidelines on cancer-related thrombosis

References

• Alikhan R, Cohen AT, Combe S et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch. Intern. Med.164, 963–968 (2004).
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch. Intern. Med.160, 809–815 (2000).
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med.166, 458–464 (2006).
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)78, 285–291 (1999).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med.343, 1846–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Akl EA, Kamath G, Kim SY et al. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review. J. Exp. Clin. Cancer Res.26, 175–184 (2007).
   PubMedGoogle Scholar
• Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer110, 1149–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Akl EA, Barba M, Rohilla S et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev.2, CD006650 (2008).
   Google Scholar
• Akl EA, Rohilla S, Barba M et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst. Rev.1, CD006649 (2008).
   Google Scholar
• Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol.9(6), 577–584 (2008).
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb. Res.123, 837–844 (2009).
   PubMed Web of Science ®Google Scholar
• Ferretti G, Bria E, Giannarelli D et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest130, 1808–1816 (2006).
   PubMed Web of Science ®Google Scholar
• Mandala M, Falanga A, Piccioli A et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit. Rev. Oncol. Hematol.59(3), 194–204 (2006).
   PubMed Web of Science ®Google Scholar
• Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist12, 1361–1370 (2007).
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol.25, 5490–5505 (2007).
   PubMed Web of Science ®Google Scholar
• Farge D, Bosquet L, Kassab-Chahmi D et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit. Rev. Oncol. Hematol.73, 31–46 (2010).
   PubMed Web of Science ®Google Scholar
• Debourdeau P, Kassab Chahmi D, Le Gal G et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann. Oncol.20, 1459–1471 (2009).
   PubMed Web of Science ®Google Scholar
• Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann. Oncol.20(Suppl. 4), 182–184 (2009).
   PubMedGoogle Scholar
• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 381S–453S (2008).
   PubMed Web of Science ®Google Scholar
• Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133(6 Suppl.), 454S–545S (2008).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Tapson VF, Bergmann JF et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet371, 387–394 (2008).
   PubMed Web of Science ®Google Scholar
• Kucher N, Spirk D, Kalka C et al. Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients Swiss Venous Thromboembolism Registry (SWIVTER). J. Thromb. Haemost.6, 2082–2087 (2008).
   PubMed Web of Science ®Google Scholar
• Imberti D, Agnelli G, Ageno W et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica93, 273–278 (2008).
   PubMed Web of Science ®Google Scholar
• Monreal M, Falga C, Valdes M et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J. Thromb. Haemost.4, 1950–1956 (2006).
   PubMed Web of Science ®Google Scholar
• AGREE collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual. Saf. Health Care12(1), 18–23 (2003).
   PubMed Web of Science ®Google Scholar
• Hadley SA, Chang M, Rogers K. Effect of syringe size on bruising following subcutaneous heparin injection. Am. J. Crit. Care5, 271–276 (1996).
   PubMedGoogle Scholar
• Debourdeau P, Elalamy I, de Raignac A et al. Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support. Care Cancer16, 1333–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch. Intern. Med.162, 1729–1735 (2002).
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am. J. Med.119, 1062–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker R, Gent M; for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med.349, 146–153 (2003).
   PubMed Web of Science ®Google Scholar
• Sideras K, Schaefer PL, Okuno SH et al. Low-molecular-weight heparin in patients with advanced cancer: a Phase 3 clinical trial. Mayo Clin. Proc.81, 758–767 (2006).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Falanga A, Piccioli A. Cancer, thrombosis and heparin-induced thrombocytopenia. Thromb. Res.120(Suppl. 2), S137–S140 (2007).
   Google Scholar
• Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol.23, 2130–2135 (2005).
   PubMed Web of Science ®Google Scholar
• Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat. Med.19, 197–201 (2005).
   PubMed Web of Science ®Google Scholar
• Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ332, 577–580 (2006).
   PubMedGoogle Scholar
• Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics24, 593–607 (2006).
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ146, 473–481 (1992).
   PubMed Web of Science ®Google Scholar
• Kryworuchko J, Stacey D, Bai N, Graham ID. Twelve years of clinical practice guideline development, dissemination and evaluation in Canada (1994 to 2005). Implement. Sci.4, 49 (2009).
   PubMedGoogle Scholar